Adverse reactions are listed as follows by system organ class and frequency.
The following convention has been used for the classification of adverse reactions in terms of frequency: Very common ≥1/10, common ≥1/100 to <1/10, uncommon ≥1/1000 to <1/100, rare ≥1/10,000 to <1/1000, very rare <1/10,000.
Blood and lymphatic system disorders: Very common: Haemorrhagic manifestations at various sites, more frequent in patients with other risk factors (see Contraindications and Interactions).
Rare: Thrombocytopenia, (including heparin-induced thrombocytopenia) (see Precautions), thrombocytosis.
Very rare: Eosinophilia, reversible following treatment discontinuation.
Immune system disorders: Very rare: Hypersensitivity reactions (including angioedema and cutaneous reactions), anaphylactoid reaction.
Very rare: Reversible hyperkalaemia related to heparin-induced aldosterone suppression, particularly in patients at risk (see Precautions).
Reproductive system and breast disorders: Very rare: Priapism.
Skin and subcutaneous tissue disorders: Rare: Rash, urticaria, erythema, pruritus.
Investigations: Common: Transaminases increased, usually transient.
General disorders and administration site conditions: Very common: Injection site haematoma.
In some cases, the emergence of firm nodules, which do not indicate an encystment of the heparin may be noted. These nodules usually disappear after a few days.
Common: Injection site reaction.
Rare: Injection site calcification. Calcification is more frequent in patients with abnormal calcium phosphate product, such as in some cases of chronic renal failure.
Very rare: Injection site necrosis (see Precautions).